Analyst Expectations for TG Therapeutics's Future
Portfolio Pulse from Benzinga Insights
Over the last quarter, TG Therapeutics (NASDAQ:TGTX) has received a mix of bullish and bearish ratings from analysts. The company's average 12-month price target is $24.8, a decrease of 5.42% from the previous average of $26.22. Analysts' ratings are based on research, company financial statements, and insider communication.
October 20, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
TG Therapeutics has received mixed analyst ratings over the last quarter, with an average 12-month price target of $24.8, down 5.42% from the previous average.
The mixed analyst ratings indicate uncertainty about the company's future performance. The decrease in the average price target suggests that analysts have lowered their expectations for the stock, which could influence investor sentiment and potentially impact the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100